Taysha Gene Therapies' (TSHA) "Buy" Rating Reaffirmed at Needham & Company LLC

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports. They presently have a $6.00 target price on the stock. Needham & Company LLC's price target would suggest a potential upside of 192.68% from the company's previous close.

Several other research firms also recently commented on TSHA. Canaccord Genuity Group upped their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a "buy" rating in a research note on Friday, November 15th. Chardan Capital reissued a "buy" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, November 14th. JMP Securities reaffirmed a "market outperform" rating and set a $5.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies has an average rating of "Buy" and a consensus target price of $6.63.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA traded up $0.13 during mid-day trading on Monday, hitting $2.05. 3,378,843 shares of the stock were exchanged, compared to its average volume of 2,144,514. The firm's 50-day simple moving average is $2.10 and its 200 day simple moving average is $2.16. The stock has a market capitalization of $420.13 million, a price-to-earnings ratio of 3.25 and a beta of 0.95. Taysha Gene Therapies has a fifty-two week low of $1.19 and a fifty-two week high of $4.32. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51.

Institutional Investors Weigh In On Taysha Gene Therapies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Creative Planning bought a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth $28,000. Principal Financial Group Inc. bought a new position in shares of Taysha Gene Therapies in the second quarter worth about $48,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Taysha Gene Therapies by 79.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company's stock valued at $79,000 after purchasing an additional 17,446 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Taysha Gene Therapies during the 3rd quarter valued at approximately $85,000. Finally, Scientech Research LLC acquired a new position in Taysha Gene Therapies during the 2nd quarter worth approximately $97,000. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.